REM
171 results
1 - 100- Overview of Risk Evaluation and Mitigation Systems (REMS)
- ISOtretinoin
- tolvaptan
- thalidomide
- pomalidomide
- lenalidomide
- vandetanib
- macitentan
- vigabatrin
- remdesivir
- bosentan
- pegvaliase
- alosetron
- flibanserin
- brodalumab
- inotersen
- eculizumab
- ambrisentan
- metreleptin
- teclistamab
- denosumab
- duvelisib
- miFEPRIStone
- remimazolam
- cloZAPine
- lomitapide
- ravulizumab
- elotuzumab
- alvimopan
- riociguat
- loxapine
- teduglutide
- esketamine
- brexanolone
- sodium oxybate
- natalizumab
- OLANZapine
- alemtuzumab
- collagenase clostridium histolyticum
- phentermine/topiramate
- testosterone topical gel
- buprenorphine/naloxone
- peginesatide
- panobinostat
- pexidartinib
- melphalan
- mycophenolate mofetil
- daclizumab
- hydroxyurea
- ezogabine
- mipomersen
- parathyroid hormone
- secobarbital
- albiglutide
- butorphanol
- fentaNYL (transdermal)
- levorphanol
- meperidine
- oxyMORphone
- SUFentanil
- buprenorphine
- How to Use Davis's Drug Guide For Nurses
- HYDROmorphone
- methadone
- tapentadol
- amobarbital
- codeine
- FENTANYL (transmucosal)
- fentanyl iontophoretic transdermal system
- oxyCODONE
- morphine
- traMADol